Lower Level of MAPK Expression Is Associated with Anthracycline Resistance and Decreased Survival in Patients with Hormone Receptor Negative Breast Cancer

Introduction: Hormone receptor negative breast cancer is encountered in about 30% of all patients with breast cancer and is considered as a prognostically unfavorable subset. The aim of this study is to evaluate the prognostic impact of various molecular markers in patients with receptor negative breast cancer. Methods: Tumor specimens from 140 patients with receptor negative (ER, PR) breast cancer were analyzed for MAPK, Her-2/neu, EGFR and PI3K expression by immunohistochemistry. The prognostic significance of these molecular factors, in addition to various prognostic variables were determined with respect to disease-free and overall survival.Results: Nineteen (13.6%), 45 (32.1%), 16 (11.4%) and 47 (33.5%) patients had positive staining for EGFR, PI3K, Her-2/neu and MAPK, respectively. Twenty-three patients with positive MAPK (16.4%) had a high level of expression (score 4–7) and 24 (17.1%) had a low score (1–3). A lower percentage of MAPK expression was significantly associated with a poorer OS (p = 0.03) and a tendency for shorter DFS (p = 0.08) among those who were positive for MAPK. Anthracycline resistance remained the only independent significant variable for OS by Cox regression analysis (p = 0.001, HR:26.1). In patients with recurrent disease, median survival after initial relapse was 16.8 months. MAPK was determined as the only prognostic factor for this endpoint. Patients with higher level of MAPK staining showed significantly shorter survival following initial recurrence (p = 0.04). Conclusion: MAPK expression is a significant prognostic factor for non-metastatic patients with hormone receptor breast cancer. A lower level of staining is shown to be associated with with antracycline resistance and oveall survival, whereas a higher expression level is correlated with shorter survival following initial relapse, suggesting possible role of different molecular mechanisms pertaining to tumor progression once recurrence occurs. Further translational research is required to elucidate molecular mechanisms of the cross-talk between intracellular signaling and molecular pathways leading to drug resistance in patients with receptor negative breast cancer.

[1]  R. Orlowski,et al.  Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. , 2007, Cancer research.

[2]  Wolfgang Heller,et al.  Triple-negative breast cancer: therapeutic options. , 2007, The Lancet. Oncology.

[3]  J. Weidhaas,et al.  Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Sung-Bae Kim,et al.  Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. , 2006, Human pathology.

[5]  A. Chinnaiyan,et al.  Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. , 2006, Cancer research.

[6]  C. Perou,et al.  AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. , 2005, The Journal of clinical investigation.

[7]  R. Schiff,et al.  Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[9]  S. Hilsenbeck,et al.  Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. , 2004, Journal of the National Cancer Institute.

[10]  Lajos Pusztai,et al.  Prognostic significance of phosphorylated P38 mitogen‐activated protein kinase and HER‐2 expression in lymph node‐positive breast carcinoma , 2004, Cancer.

[11]  B. Moon,et al.  Secretory carcinoma of the breast , 2003, Journal of clinical ultrasound : JCU.

[12]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. Neve,et al.  Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells , 2002, Oncogene.

[14]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[15]  R. McPherson,et al.  The role of mitogen-activated protein (MAP) kinase in breast cancer , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[16]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  F. Kern,et al.  Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells , 2001 .

[18]  I. Ellis,et al.  Phosphorylation of ERK1/2 mitogen‐activated protein kinase is associated with poor response to anti‐hormonal therapy and decreased patient survival in clinical breast cancer , 2001, International journal of cancer.

[19]  M. Mathieu,et al.  c‐erbB‐2 (HER‐2/neu) gene amplification is a better indicator of poor prognosis than protein over‐expression in operable breast‐cancer patients , 2001, International journal of cancer.

[20]  M. Cobb,et al.  Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. , 2001, Endocrine reviews.

[21]  S. Eppenberger-Castori,et al.  Potential prognostic value of mitogen‐activated protein kinase activity for disease‐free survival of primary breast cancer patients , 2000, International journal of cancer.

[22]  Nissi M. Varki,et al.  Ras activation in human breast cancer , 2000, Breast Cancer Research and Treatment.

[23]  J. Nesland,et al.  The prognostic value of p53 and c‐erb b‐2 immunostaining is overrated for patients with lymph node negative breast carcinoma , 2000, Cancer.

[24]  Shousha,et al.  Adenoid cystic carcinoma of the breast: a tumour commonly devoid of oestrogen receptors and related proteins , 1999, Histopathology.

[25]  Rakesh Kumar,et al.  Estrogen Receptor Expression and Function in Long-Term Estrogen-Deprived Human Breast Cancer Cells* * This work was supported by Grants NIH-RO-1-65622-04 (to R.J.S.), HD-25719 (to M.A.S.), GM-55985 and CA-44579 (to T.P.B.), and CA-65746 (to R.K.). , 1998, Endocrinology.

[26]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, Stem cells.

[27]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  G. Evan,et al.  Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB , 1997, Nature.

[29]  D T Denhardt,et al.  Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. , 1996, The Biochemical journal.

[30]  B. Asselain,et al.  Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. , 1996, British Journal of Cancer.

[31]  A. Schauer,et al.  The prognostic effect of histological tumor grade in node-negative breast cancer patients , 1993, Breast Cancer Research and Treatment.

[32]  L S Freedman,et al.  Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index , 1991, Cancer.

[33]  A. Harris,et al.  c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.

[34]  W D Dupont,et al.  Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading , 1984, Cancer.

[35]  G. Hortobagyi,et al.  Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry , 2009, Pathology Oncology Research.

[36]  S. Küçücük,et al.  MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Ian O Ellis,et al.  Prognostic markers in triple‐negative breast cancer , 2007, Cancer.

[38]  Stephen L. Abrams,et al.  Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. , 2006, Advances in enzyme regulation.

[39]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[40]  A. Oh,et al.  Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. , 2001, Molecular endocrinology.

[41]  Ji-ping Wang,et al.  Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. , 2000, Endocrinology.

[42]  Rakesh Kumar,et al.  Estradiol Hypersensitivity and Mitogen-Activated Protein Kinase Expression in Long-Term Estrogen Deprived Human Breast Cancer Cells in Vivo1. , 2000, Endocrinology.

[43]  A. Marotta,et al.  Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer. , 1999, Anticancer research.

[44]  C R King,et al.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.